SEC Form 5 · accession 0001571049-15-001225
Cyclacel Pharmaceuticals, Inc. · CYCC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Spiro George Rombotis
Officer — President & CEO · Director
Period of report
Dec 31, 2014
Accepted (ET)
Feb 17, 2015 · 6:44 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001130166
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.001 par value per shareF1,F2 | Dec 6, 2014 | F | 3,891 | $2.99 | D | 237,525 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reduction adjustment to previously reported Restricted Stock Unit award with regard to Federal and state withholding taxes paid by the Company on behalf of the employee.
- F2Of the shares of common stock reported, 142 shares are held indirectly by Mr. Rombotis through his IRA account.